Canakinumab treatment in children with familial Mediterranean fever: report from a single center

Yazilitas F., AYDOĞ Ö., ÖZLÜ S. G. , Cakici E. K. , Gungor T., Eroglu F. K. , ...Daha Fazla

RHEUMATOLOGY INTERNATIONAL, cilt.38, sa.5, ss.879-885, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Konu: 5
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1007/s00296-018-3993-5
  • Sayfa Sayıları: ss.879-885


Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5-10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.